A similar result was obtained when using a six-gene (AGR2, SLC44A4, TBC1D9, FOXA1, GATA3, and CA12) breast cancer steroid response module [40] (Kruskal-Wallis p = 0.01 across all patients, p = 0.94 in HRDetect-high patients, and p = 0.02 in HRDetect-low/intermediate patients) (Additional file 1I). This evidence concerns the gene TBC1D9 and breast cancer.